Amikacin

C difficile risk
Low
Oral Bioavailability
N/A
Cost
$81/day

Dosing

Defined criteria for use and/or important safety considerations. See below for more information.

No adjustment required

See nomograph (below)

General Information

  • Treatment of Gram-negative microorganisms that are resistant to other antimicrobials

  • Treatment of severe nontuberculous mycobacterial infections in which amikacin is indicated because of lack of response, resistance or adverse reactions to other treatments

Gram-positive and anaerobic bacteria are not susceptible to aminoglycosides

Increased nephrotoxicity with:

  • Amphotericin B

  • Cyclosporine

  • Cisplatin

  • NSAIDS

  • Contrast dye

  • Vancomycin

Increased ototoxicity with:

  • Furosemide

Respiratory paralysis with:

  • Neuromuscular blockade agents

Formal audiology assessment recommended if planning to use aminoglycoside for >14d or if symptoms develop.

Inform patient of risk of ototoxicity and to report any symptoms immediately.

Antimicrobial class: Aminoglycoside

Pregnancy category: D

Average serum half life: 2.5 hours

Biliary penetration: Moderate

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Therapeutic

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.